What Factors Are Escalating the Demand Across the Adeno-Associated Virus Vector-Based Gene Therapy Market?

0
0

The increasing prevalence of genetic disorders and the growing adoption of gene therapy have propelled substantial expansion in the AAV vector-based gene therapy domain. According to detailed industry evaluation, the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68% during the forecast period. AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9 serotypes remain among the most sought-after vector platforms globally due to their low immunogenicity, broad tissue tropism, and ability to deliver therapeutic genes for long-term expression. Furthermore, the rising prevalence of genetic disorders, growing focus on personalized medicine, and supportive government initiatives are broadening the adoption base across hematological malignancies, neurological disorders, cardiovascular diseases, ophthalmic diseases, and oncology.

The market is driven by advancements in gene editing technologies and increasing prevalence of genetic disorders. Key players including Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V. are actively pursuing product innovations and strategic partnerships. Among the leading players, Biogen stands out as a leader with its approved product Zolgensma for spinal muscular atrophy. Novartis is a significant competitor with its Zolgensma gene therapy for spinal muscular atrophy, the first approved treatment of its kind. In Q4 2024, the FDA approved PTC Therapeutics' Kebilidi, the first AAV gene therapy delivered directly into the brain. Do you think AAV gene therapy will eventually become the standard treatment for genetic disorders?

FAQs

What is the current market size of the AAV vector-based gene therapy market?
The market was valued at USD 5.718 billion in 2024 and is projected to reach USD 70.67 billion by 2035, exhibiting a CAGR of 25.68%.

Which segment dominates the AAV gene therapy market?
AAV9 holds the largest market share by vector serotype, while intravenous administration leads by route. Oncology represents the largest disease type segment.

Who are the key players in the AAV gene therapy market?
Key players include Spark Therapeutics, Bayer AG, Novartis AG, Bristol-Myers Squibb, GSK, Pfizer Inc., Sarepta Therapeutics, Astellas Pharma Inc., and UniQure N.V.

#AAVGeneTherapyMarket #GeneTherapy #GeneticDisorders #PrecisionMedicine #Biotechnology

Site içinde arama yapın
Kategoriler
Read More
Lançamentos & Anúncios
Sustainability and Environmental Impact
Conventional feminine care products have a significant environmental impact. Disposable pads and...
By Yogita Bankar 2026-09-30 09:57:51 0 0
Oyunlar
Data Privacy Concern – Facebook Users at Risk
Data Privacy Concern: Potential Information Leak Affects Facebook Users A serious security...
By Xtameem Xtameem 2026-02-28 20:54:09 0 0
Oyunlar
The 2025 Action-Platformer Trifecta That Still Owns My 2026 Playlist
I still measure 2025 by the nights I lost to three very different blades. As a player who keeps a...
By Xtameem Xtameem 2026-10-27 05:40:42 0 0
Memes & Cultura da Comunidade
Quantum Networking Market Research Report: Revenue Analysis, Market Share & Future Growth
Quantum Networking Market Size, Share, Growth Analysis, and Industry Report The Quantum...
By Prashant Manjarekar 2026-08-06 08:04:22 0 0
Oyunlar
Ready or Not 2: Sequel in Development
A sequel to the 2019 horror film Ready or Not is reportedly in development. According to a recent...
By Xtameem Xtameem 2026-06-19 20:36:31 0 0